HR-2831 : Still Just a Bill


Prompt Approval of Safe Generic Drugs Act

This bill authorizes the Food and Drug Administration (FDA) to approve certain applications to market a drug even if the drug's labeling lacks certain safety information.

Specifically, an abbreviated application for approval of a generic drug shall not be ineligible for approval solely because the drug's labeling omits safety information that is protected under another drug's exclusivity protections. Similarly, a drug that is approved under this bill shall not be considered mislabeled for lacking such safety information.

Generally, an abbreviated application, for the purposes of this bill, is one that (1) uses required information from studies not conducted by the applicant; or (2) seeks approval of a drug that is, for drug approval purposes, a duplicate of an already-approved drug.

For any drug approved under this bill, the FDA shall require the drug's labeling to include any safety information that is necessary to assure safe use.

Action Timeline

Action DateTypeTextSource
2021-04-27CommitteeReferred to the Subcommittee on Health.House committee actions
2021-04-26IntroReferralReferred to the House Committee on Energy and Commerce.House floor actions
2021-04-26IntroReferralIntroduced in HouseLibrary of Congress

Sponsor :

Nanette Diaz Barragán [D] (CA-44)
See Cosponsors

Policy Area :

Health
Related Subjects
  • Drug safety, medical device, and laboratory regulation
  • Marketing and advertising
Related Geographic Entities
Related Organizations

Related Bills

See Related Bills